Haisco Pharmaceutical Group (002653.SZ) has received approval for the clinical trial of its innovative drug HSK51155 tablets.

Haisco Pharmaceutical Group (002653.SZ) announced that the company recently received the "Notice of Approval for Clinical Trials" issued by the National Medical Products Administration. Upon review, the clinical trial application for HSK51155 tablets, submitted in June 2026, meets the relevant requirements for drug registration, and approval has been granted for this product to conduct clinical trials. HSK51155 is an orally administered small molecule analgesic drug independently researched by the company, intended for clinical use in the treatment of pain-related conditions. In April 2026, the company reached a cooperation agreement with AbbVie Group Holdings Ltd. (hereinafter referred to as "AbbVie") regarding HSK51155 and other related projects, granting AbbVie exclusive rights to develop, produce, and commercialize globally, except for mainland China, the Hong Kong Special Administrative Region, and the Macao Special Administrative Region, with a potential total transaction amount exceeding 700 million USD.